Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Semiconductors and biotech are pulling opposite ends of the options market this week. Negative bet volume is concentrated in chip names, while a handful of large-caps are drawing near-total bullish flow.
NVDA sits at the top of negative options bets over the past seven days, joined by AMD and MU. AMD is up 177% year-to-date and received a boost Tuesday when Fermi secured AMD backing for a new Texas AI project. Despite the bullish newsflow, put pressure in the name is notable. Micron, up 247% this year, also features heavily on the negative bets list.
On the bullish side, options flow is strikingly one-sided for a cluster of large-caps. ADP, EQIX, , and each show 100% positive options flow over seven days. That kind of uniformity is unusual and suggests coordinated call buying ahead of upcoming earnings prints.
MRNA carries a short score of 50 and is up 625% year-to-date. ORTEX Index Rebalance Radar puts its MSCI World addition probability at 90%, pointing to $4.8bn of forced buying across just 1.2 days of volume when the November review announcement drops on 11 November. That potential forced buying may be drawing speculative call interest now.
GM reports on 20 October. German car registration data, which ORTEX Alt Data measures as leading GM revenue by 15 days, is running 133% above the same quarter last year across three straight months. That reading has options traders watching the print closely. The stock's analyst return potential sits at 26%.
SKYD is a separate story entirely. Short interest surged 37% in a week to 132 million shares, while borrow availability collapsed to 26%, its lowest in 52 weeks. That setup, tight availability with rapidly building short interest, is where short squeeze potential tends to build fastest.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
